tiprankstipranks
Advertisement
Advertisement

TRVI Stock Latest News

Trevi Therapeutics Targets Refractory Chronic Cough With Fresh Phase 2 Trial
Company AnnouncementsTrevi Therapeutics Targets Refractory Chronic Cough With Fresh Phase 2 Trial
15h ago
TRVI
Trevi Therapeutics Targets IPF Chronic Cough With New Phase 3 Trial
PremiumCompany Announcements
Trevi Therapeutics Targets IPF Chronic Cough With New Phase 3 Trial
15h ago
TRVI
Trevi Therapeutics Shareholders Approve Stock and Governance Changes
PremiumCompany Announcements
Trevi Therapeutics Shareholders Approve Stock and Governance Changes
1M ago
8K
TRVI
Trevi Therapeutics price target raised to $30 from $18 at Stifel
PremiumThe Fly
Trevi Therapeutics price target raised to $30 from $18 at Stifel
2M ago
TRVI
Trevi Therapeutics price target raised to $29 from $21 at Clear Street
PremiumThe Fly
Trevi Therapeutics price target raised to $29 from $21 at Clear Street
2M ago
TRVI
Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley
PremiumThe FlyTrevi Therapeutics price target raised to $20 from $18 at Morgan Stanley
2M ago
TRVI
Trevi Therapeutics Charts Cash-Rich Path Through Key Trials
Premium
Company Announcements
Trevi Therapeutics Charts Cash-Rich Path Through Key Trials
2M ago
TRVI
Analyst Reiterates Buy on Trevi Therapeutics, Slightly Lowers Price Target to $23 Amid Advancing Haduvio Pipeline
Premium
Ratings
Analyst Reiterates Buy on Trevi Therapeutics, Slightly Lowers Price Target to $23 Amid Advancing Haduvio Pipeline
2M ago
TRVI
Unusually active option classes on open April 17th
PremiumThe Fly
Unusually active option classes on open April 17th
3M ago
UBS
UMC
Trevi Therapeutics Prices Public Offering to Fund Haduvio
PremiumCompany Announcements
Trevi Therapeutics Prices Public Offering to Fund Haduvio
3M ago
8K
TRVI
Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00
PremiumThe Fly
Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00
3M ago
TRVI
Closing Bell Movers: Netflix down 9% as Q2 outlook misses, Hastings leaves board
PremiumThe Fly
Closing Bell Movers: Netflix down 9% as Q2 outlook misses, Hastings leaves board
3M ago
AA
CNS
Trevi Therapeutics announces $150M common stock offering
PremiumThe FlyTrevi Therapeutics announces $150M common stock offering
3M ago
TRVI
Trevi Therapeutics: Positive Needham Conference Takeaways Reinforce Buy Rating and Favorable Risk‑Reward Profile
Premium
Ratings
Trevi Therapeutics: Positive Needham Conference Takeaways Reinforce Buy Rating and Favorable Risk‑Reward Profile
3M ago
TRVI
Trevi Therapeutics price target lowered to $24 from $25 at JonesResearch
Premium
The Fly
Trevi Therapeutics price target lowered to $24 from $25 at JonesResearch
4M ago
TRVI
Trevi Therapeutics Maps Phase III Path and Runway
PremiumCompany Announcements
Trevi Therapeutics Maps Phase III Path and Runway
4M ago
TRVI
Trevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley
PremiumThe Fly
Trevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley
4M ago
TRVI
Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)
PremiumThe Fly
Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)
4M ago
TRVI
Trevi Therapeutics options imply 6.8% move in share price post-earnings
PremiumThe Fly
Trevi Therapeutics options imply 6.8% move in share price post-earnings
4M ago
TRVI
TRVI Earnings this Week: How Will it Perform?
PremiumPre-EarningsTRVI Earnings this Week: How Will it Perform?
4M ago
TRVI
Trevi Therapeutics Aligns With FDA on Phase 3 Cough Trials
Premium
Company Announcements
Trevi Therapeutics Aligns With FDA on Phase 3 Cough Trials
4M ago
8K
TRVI
De-Risked Phase 3 Strategy and FDA Alignment Underpin Buy Rating on Trevi for Haduvio in IPF Cough
Premium
Ratings
De-Risked Phase 3 Strategy and FDA Alignment Underpin Buy Rating on Trevi for Haduvio in IPF Cough
4M ago
TRVI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >